Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study.
Amonafide 300 mg/M2 was administered intravenously on a daily x 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.
Taylor
Sarah A
SA
University of Kansas Medical Center, Kansas City, USA.
Rankin
Cathryn
C
Townsend
Jeannette J
JJ
Craig
Johnny B
JB
Vance
Ralph B
RB
Solank
Dilip L
DL
Brown
Thomas D
TD
Jaeckle
Kurt
K
D000225:Adenine; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007094:Imides / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D007262:Infusions, Intravenous; D007546:Isoquinolines / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D008297:Male; D053644:Naphthalimides; D063065:Organophosphonates
D000970:Antineoplastic Agents; D007094:Imides; D007546:Isoquinolines; D053644:Naphthalimides; D063065:Organophosphonates; C037020:amonafide; D000225:Adenine